HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adam J Shuhendler Selected Research

LM11A-31

1/2018TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31.
1/2017[18F]GE-180 PET Detects Reduced Microglia Activation After LM11A-31 Therapy in a Mouse Model of Alzheimer's Disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Adam J Shuhendler Research Topics

Disease

13Neoplasms (Cancer)
05/2022 - 01/2007
7Breast Neoplasms (Breast Cancer)
01/2019 - 01/2007
2Disease Progression
10/2022 - 01/2018
2Ovarian Neoplasms (Ovarian Cancer)
05/2022 - 01/2019
1Lung Neoplasms (Lung Cancer)
10/2021
1Uterine Cervical Neoplasms (Cancer of the Cervix)
01/2019
1Huntington Disease (Huntington's Disease)
01/2018
1Neuroinflammatory Diseases
01/2018
1Alzheimer Disease (Alzheimer's Disease)
01/2017
1Weight Loss (Weight Reduction)
08/2014
1Cardiotoxicity
08/2014
1Pathologic Processes
08/2014
1Adenocarcinoma
08/2013
1Sarcoma (Soft Tissue Sarcoma)
08/2013
1Migraine Disorders (Migraine)
07/2009
1Poisoning
01/2007

Drug/Important Bio-Agent (IBA)

4Doxorubicin (Adriamycin)FDA LinkGeneric
01/2019 - 01/2007
3Pharmaceutical PreparationsIBA
05/2022 - 01/2007
3PolymersIBA
09/2015 - 01/2010
3Mitomycin (Mitomycin-C)FDA LinkGeneric
08/2014 - 01/2007
2Biomarkers (Surrogate Marker)IBA
10/2022 - 01/2018
2LM11A-31IBA
01/2018 - 01/2017
2LipidsIBA
08/2014 - 01/2010
2AnthracyclinesIBA
08/2014 - 01/2010
2Biological ProductsIBA
09/2011 - 03/2011
1Cisplatin (Platino)FDA LinkGeneric
05/2022
1Vitamin B 6IBA
10/2021
1PyridoxalIBA
10/2021
1talazoparibIBA
01/2019
14-(3-fluoropropyl)glutamic acidIBA
01/2019
1Poly(ADP-ribose) Polymerase InhibitorsIBA
01/2019
1Glucose (Dextrose)FDA LinkGeneric
01/2019
1Indicators and Reagents (Reagents)IBA
01/2019
1Poly Adenosine Diphosphate RiboseIBA
01/2019
1Glutamic Acid (Glutamate)FDA Link
01/2019
1LigandsIBA
01/2018
1Oxygen (Dioxygen)IBA
12/2016
1Singlet OxygenIBA
12/2016
11-phenyl-3,3-dimethyltriazene (PDT)IBA
12/2016
1Reactive Oxygen Species (Oxygen Radicals)IBA
12/2016
1Photosensitizing Agents (Photosensitizers)IBA
12/2016
1Contrast MediaIBA
10/2015
1diketopyrrolopyrrole dyeIBA
09/2015
1Glucose OxidaseIBA
06/2015
1Caspase 3 (Caspase-3)IBA
10/2014
1SolutionsIBA
10/2014
11-dodecylpyridoxal (PLD)IBA
08/2014
1Ethylene Glycol (Monoethylene Glycol)IBA
08/2014
1Drug CombinationsIBA
08/2014
1Proteins (Proteins, Gene)FDA Link
08/2013
1matrigelIBA
08/2013
1Liposomes (Liposome)IBA
09/2012
1IntegrinsIBA
09/2012
1MicellesIBA
09/2012
1Lipid NanoparticlesIBA
09/2012
1cyclic arginine-glycine-aspartic acid peptideIBA
09/2012
1Type A Botulinum Toxins (Botox)FDA Link
07/2009
1DNA (Deoxyribonucleic Acid)IBA
01/2007

Therapy/Procedure

7Therapeutics
10/2022 - 09/2012
4Drug Therapy (Chemotherapy)
10/2015 - 09/2012
2Radiotherapy
01/2019 - 10/2015
1Oral Administration
01/2018
1Photochemotherapy (Photodynamic Therapy)
12/2016
1Microspheres (Microsphere)
06/2015
1Intravenous Administration
10/2014
1Treatment Delay
08/2014
1Quantum Dots (Quantum Dot)
06/2012
1Injections
07/2009